Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 7 | 1.560 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 17 | 1.550 |
Why?
|
| Body Composition | 1 | 2024 | 4 | 0.880 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1 | 0.530 |
Why?
|
| Cachexia | 1 | 2017 | 2 | 0.530 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2017 | 3 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 5 | 0.530 |
Why?
|
| Middle Aged | 6 | 2024 | 494 | 0.510 |
Why?
|
| Female | 7 | 2024 | 984 | 0.480 |
Why?
|
| Male | 6 | 2024 | 1055 | 0.440 |
Why?
|
| Humans | 8 | 2024 | 1907 | 0.410 |
Why?
|
| Aged | 5 | 2024 | 418 | 0.400 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 4 | 0.340 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 6 | 0.330 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 5 | 0.310 |
Why?
|
| Body Weight | 2 | 2024 | 15 | 0.250 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 11 | 0.220 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 6 | 0.220 |
Why?
|
| Body Mass Index | 1 | 2024 | 35 | 0.220 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 10 | 0.210 |
Why?
|
| Biomarkers | 1 | 2024 | 56 | 0.210 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 30 | 0.200 |
Why?
|
| Cognition | 1 | 2024 | 73 | 0.200 |
Why?
|
| Prognosis | 2 | 2024 | 28 | 0.190 |
Why?
|
| Biochemistry | 1 | 2000 | 1 | 0.170 |
Why?
|
| Proteins | 1 | 2000 | 6 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2017 | 102 | 0.160 |
Why?
|
| Cohort Studies | 2 | 2024 | 108 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 210 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1 | 0.130 |
Why?
|
| Weight Loss | 1 | 2017 | 8 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 19 | 0.130 |
Why?
|
| Kidney Tubules | 1 | 2016 | 1 | 0.130 |
Why?
|
| Vimentin | 1 | 2016 | 1 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2016 | 3 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 5 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 6 | 0.130 |
Why?
|
| Collagen Type X | 1 | 2014 | 1 | 0.110 |
Why?
|
| Chondrocytes | 1 | 2014 | 16 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2014 | 31 | 0.110 |
Why?
|
| Adult | 2 | 2016 | 554 | 0.100 |
Why?
|
| Serum | 1 | 2010 | 1 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2010 | 43 | 0.080 |
Why?
|
| Algorithms | 1 | 2010 | 42 | 0.080 |
Why?
|
| Risk Factors | 2 | 2024 | 143 | 0.080 |
Why?
|
| Transcriptome | 1 | 2024 | 1 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2024 | 5 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 6 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2024 | 119 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2024 | 119 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 6 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 9 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 64 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 107 | 0.050 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 53 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2000 | 8 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2017 | 3 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 2 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 8 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 8 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 4 | 0.030 |
Why?
|
| Atrophy | 1 | 2016 | 9 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 8 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 11 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2016 | 4 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 2 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Computational Biology | 1 | 2014 | 3 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 17 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 19 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 22 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 12 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 6 | 0.030 |
Why?
|
| Protein Binding | 1 | 2014 | 21 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 25 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2014 | 33 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 26 | 0.030 |
Why?
|
| Mice | 1 | 2014 | 215 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 748 | 0.020 |
Why?
|